Research Summary
Analyzed using Evidence Intelligence™

Semaglutide with Insulin Improves Diabetes Control and Kidney Health

Last updated June 17, 2026

Key finding

SEM reduced FPG.

This study evaluated the effects of semaglutide combined with insulin therapy on glycemic control and renal function in elderly patients with type 2 diabetes, finding significant improvements in several metabolic parameters.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Risk of bias

Some Concerns

Save research, organize studies, and quickly find important evidence again.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

This study evaluated the effects of semaglutide combined with insulin therapy on glycemic control and renal function in elderly patients with type 2 diabetes, finding significant improvements in several metabolic parameters.

Clinical relevance

This study highlights the potential of combining semaglutide with insulin therapy to enhance glycemic control and renal health in elderly patients, a demographic often at higher risk for diabetes complications. Improved management of blood sugar and kidney function can lead to better overall health outcomes and quality of life for these patients.

Keep in mind

Limited sample size may affect generalizability. Short duration of follow-up may not capture long-term effects. Unmeasured confounders could influence outcomes.

Published in

Journal Reference

Publication details and source links for this paper.

Lan Y, Ying Y, Suraiya S. Semaglutide Combined with Insulin Therapy Improves Glycemic Control and Renal Function in Elderly Patients with Type 2 Diabetes. International Journal of Endocrinology. 2026;2026:1543983. doi:10.1155/ije/1543983

Main Effects

Fasting Plasma Glucose decreased by 2.31 mmol/L (p=0.001)

HbA1c decreased by 1.66% (p=0.001)

24-Hour Urinary Protein decreased significantly (p=0.001)

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Insulin therapy and 24-Hour Urinary Protein (24hUpr), Adverse events incidence, Endothelin-1 (ET-1), and 9 more.

Primary intervention

Insulin therapy

Primary outcomes

  • 24-Hour Urinary Protein (24hUpr)
  • Adverse events incidence
  • Endothelin-1 (ET-1)

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

12
Evidence pairs
12
Relationships
5
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 72

5

Related topics

12

Evidence pairs

772

Related studies

High relevance in at least one topic

Why it is useful

  • Contributes to 12 evidence relationships
  • Includes primary outcome data
  • Linked to 5 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Add related evidence to your Evidence Tracker

Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.

Primary evidence

Evidence relationship

Insulin Therapies and HbA1c

Related evidence

Evidence relationship

Insulin Therapies and Insulin Resistance

Save evidence

Evidence relationship

Insulin Therapies and Fasting Glucose

Save evidence

Core evidence

Study findings

The primary outcomes reported in this study.

24-Hour Urinary Protein (24hUpr)

Insulin therapy → 24-Hour Urinary Protein (24hUpr)

Insulin therapy → 24-Hour Urinary Protein (24hUpr)

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Adverse events incidence

Insulin therapy → Adverse events incidence

Insulin therapy → Adverse events incidence

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
50
Neutral
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Endothelin-1 (ET-1)

Insulin therapy → Endothelin-1 (ET-1)

Insulin therapy → Endothelin-1 (ET-1)

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Estimated glomerular filtration rate

Insulin therapy → Estimated glomerular filtration rate

Insulin therapy → Estimated glomerular filtration rate

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Fasting Plasma Glucose (FPG)

Insulin therapy → Fasting Plasma Glucose (FPG)

Insulin therapy → Fasting Plasma Glucose (FPG)

Evidence Intelligence™
EvidenceScore™
Moderate
Score 69 · Based on 2 studies
ImpactScore™
100
Very Positive
ConsistencyScore™
100
consistent
Supporting studies: Based on 2 studies
Add to Evidence Tracker

Glucose iAUC (OGTT)

Insulin therapy → Glucose iAUC (OGTT)

Insulin therapy → Glucose iAUC (OGTT)

Evidence Intelligence™
EvidenceScore™
Strong
Score 79 · Based on 3 studies
ImpactScore™
83
Positive
ConsistencyScore™
67
generally_consistent
Supporting studies: Based on 3 studies
Add to Evidence Tracker

HbA1c

Insulin therapy → HbA1c

Insulin therapy → HbA1c

Evidence Intelligence™
EvidenceScore™
Strong
Score 79 · Based on 4 studies
ImpactScore™
88
Very Positive
ConsistencyScore™
75
consistent
Supporting studies: Based on 4 studies
Add to Evidence Tracker

Homeostatic Model Assessment of Beta-cell function (HOMA-β)

Insulin therapy → Homeostatic Model Assessment of Beta-cell function (HOMA-β)

Insulin therapy → Homeostatic Model Assessment of Beta-cell function (HOMA-β)

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Insulin resistance

Insulin therapy → Insulin resistance

Insulin therapy → Insulin resistance

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Nitric Oxide (NO)

Insulin therapy → Nitric Oxide (NO)

Insulin therapy → Nitric Oxide (NO)

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Serum VEGF

Insulin therapy → Serum VEGF

Insulin therapy → Serum VEGF

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Urinary albumin-to-creatinine ratio

Insulin therapy → Urinary albumin-to-creatinine ratio

Insulin therapy → Urinary albumin-to-creatinine ratio

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

evidence suggest

Evidence Suggest

  • Fasting Plasma Glucose reduced by 2.31 mmol/L, indicating improved glycemic control.
  • HbA1c decreased by 1.66%, suggesting better long-term blood sugar management.
  • 24-Hour Urinary Protein levels decreased, indicating improved renal function.
who this applies

Who this applies to

  • Elderly patients aged 65 and older with type 2 diabetes.
  • Patients requiring insulin therapy for diabetes management.
keep in mind

Keep in Mind

  • Results may not apply to younger populations or those without diabetes.
  • Further studies are needed to confirm long-term benefits.
  • The study's findings are based on a specific treatment regimen.
between the lines

Between the Lines

  • Limited sample size may affect generalizability.
  • Short duration of follow-up may not capture long-term effects.
  • Unmeasured confounders could influence outcomes.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

This study contributes to evidence on Insulin Therapies and HbA1c, Insulin Therapies and Postprandial and OGTT Glucose.

Related evidence relationships

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does Insulin Therapies improve HbA1c?

Strong Evidence

Insulin Therapies may improve HbA1c.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    HbA1c

    EvidenceScore™ Strong | EvidenceScore™ 79.0 | strong positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 9 supporting studies with consistent results and a positive effect signal.

Limitations

  • Population details are unavailable.
9 supporting studiesUpdated: Jul 2026

Does Insulin Therapies improve insulin resistance?

Strong Evidence

Insulin Therapies appears to improve Insulin Resistance.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Insulin resistance

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on 7 supporting studies with consistent results and a positive effect signal.

Limitations

  • Population details are unavailable.
7 supporting studiesUpdated: Jul 2026

Does Insulin Therapies improve fasting glucose?

Strong Evidence

Insulin Therapies appears to improve Fasting Glucose.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Fasting Plasma Glucose (FPG)

    EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 5 supporting studies with consistent results and a positive effect signal.

Limitations

  • Population details are unavailable.
5 supporting studiesUpdated: Jul 2026

Does Insulin Therapies improve postprandial and ogtt glucose?

Strong Evidence

Insulin Therapies appears to improve Postprandial and OGTT Glucose.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Glucose iAUC (OGTT)

    EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Generally Consistent | 1 study

Why this answer: This answer is based on 4 supporting studies with consistent results and a positive effect signal.

Limitations

  • Population details are unavailable.
4 supporting studiesUpdated: Jul 2026
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.